Improved β-thalassemia treatment using protected blood stem cell transplant with toxin-free preparation and natural selection inside the body

Funding: Research was supported by the European Research Council (L.T.J.). Sponsored research agreement with Cimeio Therapeutics AG (Cimeio) (L.T.J. and T.I.C.). Decision to publish was the sole responsibility of L.T.J. L.T.J.’s employer, the Basel University Hospital, receives financial compensation for L.T.J.’s consulting. Employment: Ridgeline Discovery GmbH: A. S., A. W., L.C.W. Employment: Cimeio Therapeutics: A. C., E-M. G., E. TB., J. B., L. G. P., F. L., V. DS., C. D., S. Y., S. U. Cimeio co-founder: R.M., R.L., L.T.J. Personal financial interests: L.T.J.: co-founder, board member of Cimeio AG. Holding Cimeio equity: University of Basel, R.M., R.L., A. S., A. C., T. B., A. W., L.C.W., E-M. G., E. TB., J. B., L. G. P., F. L., V. DS., C. D., S. Y., S. U., L.T.J. Inventors on a patent application related to the findings reported here: R.M., R.L., A. S., A. C., A. W., L.C.W., E. TB., L. G. P., F. L., S. U., L.T.J. Hold a patent on CAST-Seq (US11319580B2): T.C. and G.A. D.R.L. is a co-founder of Beam Therapeutics, Prime Medicine, Pairwise Plants, Editas Medicine, and nChroma Bio, companies that use or deliver genome editing or epigenome-modifying agents.